Sanofi Pasteur Gains Updated FDA Approval for Quadracel Combination Pediatric Vaccine in March 2026

A March 12, 2026 FDA approval letter for Sanofi Pasteur's Quadracel signals active regulatory maintenance on a combination pediatric vaccine that has accumulated five approval actions since its original licensure, a pattern QA directors and regulatory affairs leads should read as a benchmark for lifecycle management under 21 CFR Part 600 biologics requirements.

Quadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine, STN BL 125525) is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis. Its approved use is narrow by design: a single dose administered as the fifth dose in the DTaP series, or as the fourth or fifth dose in the inactivated poliovirus (IPV) series, in children aged 4 through 6 years. Critically, prior vaccination history is a condition of use, eligible patients must have received previous DTaP doses exclusively with Pentacel, DAPTACEL, and/or VAXELIS.

That interchangeability restriction carries direct implications for lot release and distribution planning. Manufacturers and hospital pharmacy procurement teams operating under ICH Q10 pharmaceutical quality system principles must ensure that patient vaccination history documentation is integrated into any administration protocol, since off-label use outside the approved prior-dose sequence falls outside the licensed indication.

The approval document trail, spanning letters dated June 2019, December 2019, February 2021, July 2022, and now March 2026, reflects the iterative post-licensure supplement cycle typical of combination biologics. Each action represents a discrete regulatory event requiring internal change control reconciliation, updated batch records where applicable, and labeling version management. Plant heads overseeing fill-finish or packaging operations for combination vaccine products should confirm that their document control systems capture the current approved package insert version tied to the March 2026 letter.

For regulatory affairs teams, the cadence of approval letters also underscores FDA's ongoing review posture toward pediatric combination vaccines, a category that continues to attract post-market labeling scrutiny as real-world immunization schedule data accumulates.

The next measurable checkpoint for Quadracel's regulatory lifecycle will be whether the March 2026 approval letter reflects a labeling revision, a manufacturing supplement, or a post-market commitment closure, details that will become visible once FDA posts the associated review documents to the biologics license file.

Source: U.S. Food and Drug Administration, Vaccines, Blood and Biologics product page via FDA.gov RSS Feed, July 6, 2026.